The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C
Open accessAbstract
SUMMARY: Background Whether antidepressants prevent depression during interferon‐alpha/ribavirin treatment for hepatitis C virus infection has yet to be established. Aim To investigate the use of paroxetine in a prospective, double‐blind, placebo‐controlled study for this indication. Methods Sixty‐one hepatitis C virus‐infected patients were randomly assigned to the antidepressant, paroxetine (n = 28), or placebo (n = 33), begun 2 weeks before and continued for 24 weeks during interferon‐alpha/ribavirin treatment. Primary endpoints included development of major depression and severity of depressive symptoms measured by the Montgomery Asberg Depression Rating Scale (MADRS). Results Rates of major depression during the study were low (17%) and did not differ between groups. Nevertheless, using published MADRS cut‐off scores, the percent of subjects who met criteria for mild, moderate or severe depression during interferon‐alpha/ribavirin therapy was significantly lower in paroxetine‐ vs. placebo‐treated subjects (P = 0.02, Fisher’s exact test). Assignment to paroxetine was also associated with significantly reduced depressive symptom severity. This effect was largely accounted for by participants with depression scores above the median (MADRS > 3) at baseline in whom paroxetine was associated with a maximal reduction in MADRS scores of 10.3 (95% CI: 2.1–18.5) compared with placebo at 20 weeks (P < 0.01). Study limitations included a small sample size and high drop‐out rate. Conclusion This double‐blind, placebo‐controlled trial provides preliminary data in support of antidepressant pre‐treatment in hepatitis C virus patients with elevated depressive symptoms at baseline.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interestingly, selective serotonin (5-HT) reuptake inhibitors (SSRIs) have been shown to alleviate cytokine-induced depression (Musselman et al., 2001a, Raison et al., 2007), and depressive and anxiety symptoms appear to be most responsive, while fatigue and neurovegetative symptoms are less responsive (Capuron et al., 2002, Raison et al., 2005b, McNutt et al., 2012).”
From Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications (2013) · cites this paper as Raison et al., 2007
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C. I., Marinos, G., Gonçales, F. L., Häussinger, D., Moisés Diago, M., Carosi, G., Dhumeaux, D., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020047 · Cited by 6,386
Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M. L., Reindollar, R., Goodman, Z. D., Koury, K. J., Ling, M.-H., & Albrecht, J. K. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06102-5 · Cited by 6,027
The Fifth Edition of the Addiction Severity Index.
Mclellan, A., Kushner, H., Metzger, D., Peters, R., Smith, I. E., Grissom, G. R., Pettinati, H., & Argeriou, M. (1992) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(92)90062-s · Cited by 4,280
Handbook of Psychiatric Measures
Salzman, C. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.8.1343 · Cited by 1,172
Paroxetine for the prevention of depression induced by high-dose interferon alfa.
Musselman, D. L., Lawson, D. H., Gumnick, J. F., Manatunga, A. K., Penna, S., Goodkin, R. S., Greiner, K., Nemeroff, C. B., & Miller, A. H. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103293441303 · Cited by 1,120
Self-citationMcHutchison, J. G., Manns, M. P., Patel, K., Poynard, T., Lindsay, K. L., TREPO, C. G., Dienstag, J. L., Lee, W. M., Mak, C., Garaud, J., et al. (2002) · Gastroenterology · doi:10.1053/gast.2002.35950 · Cited by 969
Davis, G. L., Wong, J. B., McHutchison, J. G., Manns, M. P., Harvey, J., & Albrecht, J. K. (2003) · Hepatology · doi:10.1053/jhep.2003.50364 · Cited by 819
Neuropsychiatric Adverse Effects of Interferon-??: Recognition and Management
Raison, C. L., Demetrashvili, M., Capuron, L., & Miller, A. H. (2005) · CNS Drugs · doi:10.2165/00023210-200519020-00002 · Cited by 483
Self-citationShiffman, M. L., Bisceglie, A. M. D., Lindsay, K. L., Morishima, C., Wright, E. C., Everson, G. T., Lok, A. S.-F., Morgan, T. R. M., Bonkovsky, H. L., & Lee, W. M. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.01.014 · Cited by 451
Bonaccorso, S., Marino, V., Puzella, A., Pasquini, M., Biondi, M., Artini, M., Almerighi, C., Verkerk, R., Meltzer, H., & Maes, M. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200202000-00014 · Cited by 437
Neuropsychiatric Symptoms Associated With Hepatitis C and Interferon Alpha: A Review
Dieperink, E. W., Willenbring, M., & Ho, S. B. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.6.867 · Cited by 417
Schaefer, M., Schmidt, F., Folwaczny, C., Lorenz, R. L., Martin, G., Schindlbeck, N. E., Heldwein, W., Soyka, M., Grunze, H., Koenig, A., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50031 · Cited by 322
Hauser, P., Khosla, J., Aurora, H., Laurin, J. M., Kling, M. A., Hill, J., Gulati, M. S., Thornton, A. J., Schultz, R. L., Valentine, A. D., et al. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001119 · Cited by 311
Reynolds, C. R. (2008) · Encyclopedia of Special Education · doi:10.1002/9780470373699.speced1606 · Cited by 307
Depression During Pegylated Interferon-Alpha Plus Ribavirin Therapy
Raison, C. L., Borisov, A. S., Broadwell, S. D., Capuron, L., Woolwine, B. J., Jacobson, I. M., Nemeroff, C. B., & Miller, A. H. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0106 · Cited by 300
Self-citationCapuron, L., Ravaud, A., & Dantzer, R. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.10.2143 · Cited by 293
Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus
Bonaccorso, S., Marino, V., Biondi, M., Grimaldi, F., Ippoliti, F., & Maes, M. H. J. (2002) · Journal of Affective Disorders · doi:10.1016/s0165-0327(02)00264-1 · Cited by 280
A Comparison of Depression Rating Scales
Kearns, N. P., Cruickshank, C. A., McGuigan, K. J., Riley, S., Shaw, S. P., & Snaith, R. P. (1982) · The British Journal of Psychiatry · doi:10.1192/bjp.141.1.45 · Cited by 273
Psychiatric Symptoms in Patients With Chronic Hepatitis C Receiving Interferon Alfa-2b Therapy
Kraus, M. R., Schafer, A., Faller, H., Csef, H., & Scheurlen, M. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0614 · Cited by 245
Capuron, L., Ravaud, A., Miller, A. H., & Dantzer, R. (2003) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2003.11.004 · Cited by 243
Self-citationArterial Stiffness and Stroke in Hypertension
Laurent, S., & Boutouyrie, P. (2005) · CNS Drugs · doi:10.2165/00023210-200519010-00001 · Cited by 237
Bernstein, D., Kleinman, L., Barker, C. M., Revicki, D. A., & Green, J. (2002) · Hepatology · doi:10.1053/jhep.2002.31311 · Cited by 231
Dieperink, E. W., Ho, S. B., THURAS, P. D., & Willenbring, M. L. (2003) · Psychosomatics · doi:10.1176/appi.psy.44.2.104 · Cited by 217
Hepatitis C, interferon alfa, and depression
Zdilar, D., Franco-Bronson, K., Buchler, N. M., Locala, J. A., & Younossi, Z. M. (2000) · Hepatology · doi:10.1053/jhep.2000.7880 · Cited by 213
Interferon alpha (IFNα) and psychiatric syndromes
Schaefer, M., Engelbrechta, M. A., Gut, O., Fiebich, B. L., Bauer, J., Schmidt, F., Grunze, H., & Lieb, K. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(01)00324-4 · Cited by 203
Schaefer, M., Schwaiger, M., Garkisch, A. S., Pich, M. G. L., Hinzpeter, A., Uebelhack, R., Heinz, A., van Bömmel, F., & Berg, T. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.01.020 · Cited by 176
Paroxetine for the treatment of interferon‐α‐induced depression in chronic hepatitis C
Kraus, M. R., Schäfer, A., Faller, H., Csef, H., & Scheurlen, M. (2002) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2002.01265.x · Cited by 168
Treatment with interferon-α in patients with chronic hepatitis and mood or anxiety disorders
Pariante, C. M., Orrù, M. G., Baita, A., Farci, M. G., & Carpiniello, B. (1999) · The Lancet · doi:10.1016/s0140-6736(98)04793-x · Cited by 164
Mood Alterations During Interferon-Alfa Therapy in Patients With Chronic Hepatitis C
Constant, A., Castéra, L., Dantzer, R., Couzigou, P., de Lédinghen, V., Demotes‐Mainard, J., & Henry, C. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0814 · Cited by 151
Depression, anemia and health-related quality of life in chronic hepatitis C
Dan, A. A., Martin, L. M., Crone, C., Ong, J. P., Farmer, D. W., Wise, T. N., Robbins, S., & Younossi, Z. M. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.11.046 · Cited by 141
Horikawa, N., Yamazaki, T., Izumi, N., & Uchihara, M. (2003) · General Hospital Psychiatry · doi:10.1016/s0163-8343(02)00239-6 · Cited by 140
Depression From Interferon Therapy in Patients With Hepatitis C
Miyaoka, H., Otsubo, T., Kamijima, K., Ishii, M., ONUKI, M., & Mitamura, K. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.7.1120 · Cited by 135
Raison, C. L., Broadwell, S. D., Borisov, A. S., Manatunga, A. K., Capuron, L., Woolwine, B. J., Jacobson, I. M., Nemeroff, C. B., & Miller, A. H. (2004) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2004.05.001 · Cited by 131
Self-citationPsychiatric Comorbidity Among Hepatitis C-Positive Patients
Yovtcheva, S. P., Rifai, M. A., Moles, J. K., & Linden, B. J. V. D. (2001) · Psychosomatics · doi:10.1176/appi.psy.42.5.411 · Cited by 122
Fireman, M., Indest, D. W., Blackwell, A. D., Whitehead, A. J., & Hauser, P. (2005) · Clinical Infectious Diseases · doi:10.1086/427442 · Cited by 105
Sertraline treatment of interferon‐alfa‐induced depressive disorder
Schramm, T. M., Lawford, B. R., Cooksley, W. G. E., & Macdonald, G. A. (2000) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2000.tb125687.x · Cited by 104
Health-Related Quality of Life and Depression in Patients with Chronic Hepatitis C
Gallegos-Orozco, J. F., Fuentes, A. P., Argueta, J. G., Pérez-Pruna, C., Hinojosa, C. A., Sixtos-Alonso, M. S., Cruz-Castellanos, S., Gutiérrez‐Reyes, G., Olivera-Martinez, M. A., Gutiérrez‐Ruíz, M. C., et al. (2003) · Archives of Medical Research · doi:10.1016/s0188-4409(03)00003-1 · Cited by 102
Impact of treatment on extra hepatic manifestations in patients with chronic hepatitis C
Cacoub, P., Ratziu, V., Myers, R. P., Ghillani‐Dalbin, P., Piette, J. C., Moussalli, J., & Poynard, T. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00067-3 · Cited by 101
An Open-Label Trial of Citalopram for Major Depression in Patients With Hepatitis C
Gleason, O. C., Yates, W. R., Isbell, M. D., & Philipsen, M. A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0304 · Cited by 100
Kraus, M. R., Schäfer, A., Al‐Taie, O., & Scheurlen, M. (2005) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2005.00554.x · Cited by 96
Morasco, B. J., Rifai, M. A., Loftis, J. M., Indest, D. W., Moles, J. K., & Hauser, P. (2007) · Journal of Affective Disorders · doi:10.1016/j.jad.2007.01.007 · Cited by 96
Hepatitis C, alpha interferon, anxiety and depression disorders: A prospective study of 71 patients
Gohier, B., Goëb, J.-L., Rannou-Dubas, K., Fouchard, I., Calès, P., & Garré, J.-B. (2003) · The World Journal of Biological Psychiatry · doi:10.1080/15622970310029904 · Cited by 87
Maddock, C., Baita, A., Orrù, M. G., Sitzia, R., Costa, A., Muntoni, E., Farci, M. G., Carpiniello, B., & Pariante, C. M. (2004) · Journal of Psychopharmacology · doi:10.1177/0269881104040230 · Cited by 85
Early increase in vegetative symptoms predicts IFN-α-induced cognitive-depressive changes
Wichers, M., Koek, G. H., Robaeys, G., Praamstra, A. J., & Maes, M. H. J. (2004) · Psychological Medicine · doi:10.1017/s0033291704003526 · Cited by 84
Five Cases of Interferon-Alpha–Induced Depression Treated With Antidepressant Therapy
Gleason, O. C., & Yates, W. R. (1999) · Psychosomatics · doi:10.1016/s0033-3182(99)71190-4 · Cited by 80
Maskens, A. P., & Dujardin‐Loits, R. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1 · Cited by 75
Self-citationKraus, M. R., Schäfer, A., Csef, H., Faller, H., Mörk, H., & Scheurlen, M. (2001) · Digestive Diseases and Sciences · doi:10.1023/a:1011973823032 · Cited by 73
Prophylactic Treatment of Depression Induced by Interferon-α
Hauser, P., Soler, R., Reed, S., Kane, R., Gulati, M. S., Khosla, J., Kling, M. A., Valentine, A. D., & Meyers, C. A. (2000) · Psychosomatics · doi:10.1176/appi.psy.41.5.439 · Cited by 59
Khan, A., Brodhead, A. E., & Kolts, R. L. (2004) · International Clinical Psychopharmacology · doi:10.1097/00004850-200405000-00006 · Cited by 58
Maddock, C., Landau, S., Barry, K., Maulayah, P., Hotopf, M., Cleare, A. J., Norris, S., & Pariante, C. M. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001634 · Cited by 54
Hepatitis C Treatment Eligibility and Outcomes Among Patients With Psychiatric Illness
Rifai, M. A., Moles, J. K., & Short, D. D. (2006) · Psychiatric Services · doi:10.1176/ps.2006.57.4.570 · Cited by 51
Mallinckrodt, C. H., Raskin, J., Wohlreich, M. M., Watkin, J. G., & Detke, M. J. (2004) · BMC Psychiatry · doi:10.1186/1471-244x-4-26 · Cited by 50
Emotional Distress During Interferon-α-2B and Ribavirin Treatment of Chronic Hepatitis C
Fontana, R. J., Schwartz, S. M., Gebremariam, A., Lok, A. S.-F., & Moyer, C. A. (2002) · Psychosomatics · doi:10.1176/appi.psy.43.5.378 · Cited by 44
Beratis, S., Katrivanou, A., Georgiou, S., Monastirli, A., Pasmatzi, E., Gourzis, P., & Tsambaos, D. (2005) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2004.03.010 · Cited by 43
Interferon-Induced Depression Treated With Citalopram
Farah, A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0213c · Cited by 28
Guadagnino, V., Trotta, M. P., Carioti, J., Caroleo, B., & Antinori, A. (2005) · Digestive and Liver Disease · doi:10.1016/j.dld.2005.10.008 · Cited by 27
Wills, W., Trieman, N., & Leff, J. (1998) · International Journal of Geriatric Psychiatry · doi:10.1002/(sici)1099-1166(199804)13:4
Research works printed but not linked: 3
- 10.1176/appi.ps.57.4.570 · DOI
- Anonymous, 2005, Physicians’ Desk Reference
- Jacobson IM, 2005, Weight‐based ribavirin (WBD) increases sustained viral response (SVR) in patients with chronic hepatitis C (CHC): final results of the WIN‐R study, a US community based trial, Hepatol, 1, 749A
Cited by
Sorted by citations
PRACTICE GUIDELINE FOR THE Treatment of Patients With Major Depressive Disorder
Gelenberg, A. J., Freeman, P. B., Markowitz, J. C., Rosenbaum, J. F., Thase, M. E., Trivedi, M. H., & Rhoads, R. S. (2010) · Cited by 1,372
Immune system to brain signaling: Neuropsychopharmacological implications
Capuron, L., & Miller, A. H. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.01.014 · Cited by 1,195
Self-citationInflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications
Felger, J. C., & Lotrich, F. E. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.060 · Cited by 1,180
Haroon, E., Raison, C. L., & Miller, A. H. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.205 · Cited by 1,000
Self-citationThe Link between Depression and Chronic Pain: Neural Mechanisms in the Brain
Sheng, J., Shui, L., Wang, Y., Cui, R., & Zhang, X. (2017) · Neural Plasticity · doi:10.1155/2017/9724371 · Cited by 852
Metadata
- Authors
- RAISON, C. L., WOOLWINE, B. J., DEMETRASHVILI, M. F., BORISOV, A. S., WEINREIB, R., STAAB, J. P., ZAJECKA, J. M., BRUNO, C. J., HENDERSON, M. A., REINUS, J. F., EVANS, D. L., ASNIS, G. M., & MILLER, A. H.
- Affiliations
- Emory University (US)
- University of Pennsylvania (US)
- Rush University Medical Center (US)
- Kaiser Permanente (US)
- Albert Einstein College of Medicine (US)
- Corresponding author
- MILLER, A. H.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2007-03-20
- Volume
- 25
- Issue
- 10
- Pages
- 1163-1174
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W1482765914
- Cited by
- 142
- References
- 60
- Citations by year
- 2025: 1 · 2024: 1 · 2022: 4 · 2020: 4 · 2019: 3 · 2018: 3 · 2017: 3 · 2016: 3 · 2015: 11 · 2014: 8 · 2013: 23 · 2012: 17
- FWCI
- 10.96
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Alimentary Pharmacology & Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Pfizer
- National Institutes of Health
- National Institute of Mental Health (MH-00680, K23MH064619, MH 60723, MH 64619, R01MH060723, MH060723)
- National Center for Research Resources (M01-RR00039, M01RR000039)
- NIH Clinical Center
- Topics
- Health Sciences › Medicine › Hepatology › Hepatitis C virus research
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- paroxetine, antidepressant prophylaxis, depression prevention, interferon-alpha, ribavirin, hepatitis C, depressive symptoms, antiviral therapy adverse effects, Montgomery-Asberg Depression Rating Scale
- MeSH terms
- Adolescent, Adult, Aged, Antiviral Agents, Depressive Disorder, Major, Major Depressive Disorder, Double-Blind Method, Female, Humans, Male, Middle Aged, Ribavirin, Interferon-alpha, Paroxetine, Hepatitis C, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
